TMC6 Is a Novel Therapeutic Target for Pathogenic Cardiac Hypertrophy - PubMed
4 hours ago
- #heart failure
- #TMC6-CIB1 axis
- #cardiac hypertrophy
- TMC6 is a novel therapeutic target for pathogenic cardiac hypertrophy.
- TMC6 is downregulated in hypertrophic hearts and its deficiency increases cardiomyocyte size and adverse remodeling.
- TMC6 overexpression blunts hypertrophic responses by sequestering CIB1 in the endoplasmic reticulum.
- A cell-permeable TMC6 peptide competitively displaces CIB1, augmenting hypertrophy via a dominant-negative mechanism.
- AAV9-cTnT-TMC6 therapy restores TMC6-CIB1 engagement and improves heart function after pressure overload.
- The TMC6-CIB1 axis is nominated as a therapeutic target for heart failure.